JAY JEFFREY R
Filed a 13F-NT notice for 2026-09-30: this manager's Section 13(f) holdings are reported by another manager, so it no longer files its own holdings. Figures shown are from its last 13F-HR.
Sector Allocation
- Other90.4%$108,924
- Healthcare9.6%$11,559
Largest positions — Q2 2013
- HYPERION$21K
- FURIEX$17K
- STEMLINE$14K
- BIODEL$8K
- AMBIT$7K
GERN
$6K- PAIN$5K
- SUNSHINE$5K
- DURATA$5K
- NORDION$4K
- HORIZON$4K
- ONCOGENEX$3K
TRIB
$3K- RTI$3K
- DYAX$3K
- MAST$2K
PLX
$2K- VOLCANO$2K
- TARGACEPT,$2K
- XENOPORT$1K
Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.
13fpro.ai/research/fund/jay-jeffrey-r-1239607
JAY JEFFREY R 13F holdings — Q2 2013
$127K portfolio · 32 holdings · Q2 2013 13F · top 10 are 76% of the stock portfolio
Includes $6K of put/call options ($5K puts, $1K calls), which 13F rules report at the value of the underlying shares, not the premium at risk. Stocks alone: $120K. Weights use the stock portfolio.
- 1
HYPERION THERAPEUTICS INC. - COM
$21.2K
17.6% of stocks
—This quarter—Since Q-end—HeldAIQuality—Est. buy— - 2
FURIEX PHARMACEUTICAL, INC. - COM
$16.8K
14.0% of stocks
—This quarter—Since Q-end—HeldAIQuality—Est. buy— - 3
STEMLINE THERAPEUTICS INC. - COM
$14.2K
11.8% of stocks
—This quarter—Since Q-end—HeldAIQuality—Est. buy— - 4
BIODEL INC. - COM
$7.7K
6.4% of stocks
—This quarter—Since Q-end—HeldAIQuality—Est. buy— - 5
AMBIT BIOSCIENCES CORP - COM
$7.0K
5.8% of stocks
—This quarter—Since Q-end—HeldAIQuality—Est. buy— $5.6K
4.7% of stocks
—This quarter—Since Q-end1+ qtrsHeld- 7
PAIN THERAPEUTICS INC. - COM
$5.1K
4.3% of stocks
—This quarter—Since Q-end—HeldAIQuality—Est. buy— - 8
SUNSHINE HEART INC. - COM
$5.1K
4.2% of stocks
—This quarter—Since Q-end—HeldAIQuality—Est. buy— - 9
DURATA THERAPEUTICS INC. - COM
$4.6K
3.8% of stocks
—This quarter—Since Q-end—HeldAIQuality—Est. buy— - 10
NORDION INC. - COM
$4.0K
3.3% of stocks
—This quarter—Since Q-end—HeldAIQuality—Est. buy—
| # | Company | Value | Weight | This quarter | Since Q-end | Held | AI quality | Est. buy | |
|---|---|---|---|---|---|---|---|---|---|
| 1 | HYPERION THERAPEUTICS INC. - COM | $21.2K | 17.6% | — | — | — | — | — | |
| 2 | FURIEX PHARMACEUTICAL, INC. - COM | $16.8K | 14.0% | — | — | — | — | — | |
| 3 | STEMLINE THERAPEUTICS INC. - COM | $14.2K | 11.8% | — | — | — | — | — | |
| 4 | BIODEL INC. - COM | $7.7K | 6.4% | — | — | — | — | — | |
| 5 | AMBIT BIOSCIENCES CORP - COM | $7.0K | 5.8% | — | — | — | — | — | |
| 6 | $5.6K | 4.7% | — | — | 1+ qtrs | — | Estimated buy price is Pro: unlock with a free trial | ||
| 7 | PAIN THERAPEUTICS INC. - COM | $5.1K | 4.3% | — | — | — | — | — | |
| 8 | SUNSHINE HEART INC. - COM | $5.1K | 4.2% | — | — | — | — | — | |
| 9 | DURATA THERAPEUTICS INC. - COM | $4.6K | 3.8% | — | — | — | — | — | |
| 10 | NORDION INC. - COM | $4.0K | 3.3% | — | — | — | — | — |
All holdings — JAY JEFFREY R (Q2 2013)
32 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.
| # | Company | Held | Source | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 11 | — | HORIZON PHARMA, INC. - COM | — | $4K | 3.3% | 1.60M | — | — | — | 13F |
| 12 | — | ONCOGENEX PHARMACEUTICAL INC. - COM | — | $3K | 2.8% | 347K | — | — | — | 13F |
| 13 | — PUT | IMPAX LABORATORIES, INC. - COM | — | $3K | — | 150K | — | — | — | 13F |
| 14 | TRINITY BIOTECH PLCadr | Healthcare | $3K | 2.3% | 163K | — | 1+ qtrs | — | 13F | |
| 15 | — | RTI BIOLOGICS, INC. - COM | — | $3K | 2.1% | 674K | — | — | — | 13F |
| 16 | — | DYAX CORP - COM | — | $3K | 2.1% | 728K | — | — | — | 13F |
| 17 | — | MAST THERAPEUTICS INC. - COM | — | $2K | 2.1% | 5.80M | — | — | — | 13F |
| 18 | Protalix BioTherapeutics, Inc. | Healthcare | $2K | 1.6% | 399K | — | 1+ qtrs | 66.8 | 13F | |
| 19 | MYRIAD GENETICS INC | Healthcare | $2K | — | 70K | — | — | — | 13F | |
| 20 | — | VOLCANO CORPORATION - COM | — | $2K | 1.5% | 100K | — | — | — | 13F |
| 21 | — | TARGACEPT, INC. - COM | — | $2K | 1.3% | 368K | — | — | — | 13F |
| 22 | — CALL | AVANIR PHARMACEUTICALS INC. - CL A NEW | — | $1K | — | 259K | — | — | — | 13F |
| 23 | — | XENOPORT INC. - COM | — | $1K | 1.0% | 233K | — | — | — | 13F |
| 24 | — | MEI PHARMA INC. - COM NEW | — | $1K | 0.9% | 158K | — | — | — | 13F |
| 25 | — | PERNIX THERAPEUTICS HOLDINGS - COM | — | $1K | 0.9% | 297K | — | — | — | 13F |
| 26 | $PTN | PALATIN TECHNOLOGIES INC | Healthcare | $1K | 0.9% | 1.71M | — | |||
| 27 | — | VASCULAR SOLUTIONS INC. - COM | — | $680 | 0.6% | 46K | — | |||
| 28 | — | WRIGHT MEDICAL GROUP, INC. - RIGHT 03/01/2019 | — | $542 | 0.5% | 200K | — | |||
| 29 | — | CELSION CORPORATION - COM | — | $190 | 0.2% | 186K | — | |||
| 30 | $AORT | ARTIVION, INC. | Healthcare | $164 | 0.1% | 26K | — | |||
| 31 | — | GW PHARMACEUTICALS PLC - ADS | — | $102 | 0.1% | 12K | — | |||
| 32 | — | AMAG PHARMACEUTICALS, INC. - COM | — | $3 | 0.0% | 150 | — |
Is it too late to follow JAY JEFFREY R?
Holdings as of Jun 30, 2013 (SEC filing). Prices are closing prices as of Nov 19, 2026.
Average quality of JAY JEFFREY R's top 20 holdings: 65/100 (our AI quality score, weighted by position size; 2 of the 20 are scored)
Top 10 since quarter-end
—
Value-weighted move of the 10 largest stock positions
Turnover
—
Last quarter
Top 10 weight
76%
Share of the stock portfolio in its 10 largest positions
Held 4+ quarters
0%
Share of portfolio value in positions held a year or more
Highest-quality names it owns(among its 100 largest positions)
The 2 highest-scoring companies in this portfolio are a Pro feature.
How these are measured
- Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
- Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
- Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q2 2013 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
- Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
- Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.
Portfolio Overview
JAY JEFFREY R disclosed 32 positions worth $126,545 in its Form 13F-HR for Q2 2013 — $120,483 in common stock plus $6,062 of put/call option positions (reported at underlying notional value, not premium at risk). During the quarter the fund opened 32 new positions and exited 0. The portfolio is most concentrated in Other (90.4% of disclosed assets). All figures are sourced directly from JAY JEFFREY R’s Form 13F-HR filing with the SEC under CIK 1239607.
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
AI-Powered Hedge Fund Analysis: JAY JEFFREY R
13F Pro is an AI hedge fund tracker and stock research platform. For JAY JEFFREY R (SEC CIK: 1239607), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in JAY JEFFREY R's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.